It has been previously published that patients with lymphadenopathy with an LN size bigger than 50 mm receiving targeted therapies (BTK of BCL2 inhibitors) have a worse progression-free survival (PFS) compared to those with LNs of smaller dimensions [9,10]. The gene discussed is BCL2; the disease is Lymphadenopathy.